The rate and predictors of recompensation in patients with decompensated cirrhosis due to metabolic dysfunction–associated liver disease (MASLD)
Liver recompensation in MASLD cirrhosis occurs in 24% of patients within 2 years after first decompensation and is mainly dependent on basal liver function. However, frequent further decompensation limits its prognostic impact on survival.
Authors
- Laura Pagès
- J.A. Carrión (ORCID: https://orcid.org/0000-0001-7191-6081)
- J Genesca
- Alba Jiménez-Masip (ORCID: https://orcid.org/0000-0003-0502-0185)
- Juan M. Pericàs (ORCID: https://orcid.org/0000-0002-3645-3293)
- Isabel Serra-Matamala
- Cautar El Maimouni (ORCID: https://orcid.org/0009-0003-8572-7793)
- Sergio Muñoz (ORCID: https://orcid.org/0000-0003-0663-0575)
- Diego Rojo
- Isabel Graupera
- Anna Sòria
- Mònica Pons
- Pere Ginès
- M. Teresa Broquetas
Institutions
- Hebron University (PS)
- Universitat Autònoma de Barcelona (ES)
- Departament de Salut (ES)
- Vall d'Hebron Institut de Recerca (ES)
- Hospital Clínic de Barcelona (ES)
- Vall d'Hebron Hospital Universitari (ES)
- Hospital Del Mar (ES)
- Hospital Universitari de Girona Doctor Josep Trueta (ES)
- Hospital del Mar Research Institute (ES)
- Fundació Clínic per a la Recerca Biomèdica (ES)
- Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES)
- Medical Research Network (US)
- Fundació de Recerca Clínic Barcelona-Institut d’Investigacions Biomèdiques August Pi i Sunyer (ES)
- Universitat de Barcelona (ES)
Publication Details
- Journal
- Hepatology Communications
- Published
- 2026-03-11
- DOI
- https://doi.org/10.1097/hc9.0000000000000919
- Primary Topic
- Liver Disease and Transplantation
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Pfizer
- Gilead Sciences
- Asociación Española para el Estudio del Hígado
- European Federation of Pharmaceutical Industries and Associations
- European Commission
- Novo Nordisk
- Astellas Pharma
- Instituto de Salud Carlos III